Corentec Co., Ltd.

KOSDAQ:A104540 Stock Report

Market Cap: ₩56.6b

Corentec Past Earnings Performance

Past criteria checks 2/6

Corentec's earnings have been declining at an average annual rate of -3.2%, while the Medical Equipment industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 18.3% per year. Corentec's return on equity is 4%, and it has net margins of 2.9%.

Key information

-3.18%

Earnings growth rate

-5.01%

EPS growth rate

Medical Equipment Industry Growth22.66%
Revenue growth rate18.33%
Return on equity4.04%
Net Margin2.89%
Last Earnings Update31 Mar 2026

Recent past performance updates

Analysis Article • Apr 01

Shareholders Can Be Confident That Corentec's (KOSDAQ:104540) Earnings Are High Quality

The subdued stock price reaction suggests that Corentec Co., Ltd.'s ( KOSDAQ:104540 ) strong earnings didn't offer any...
Analysis Article • Dec 24

Should You Use Corentec's (KOSDAQ:104540) Statutory Earnings To Analyse It?

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...

Recent updates

Analysis Article • Apr 01

Shareholders Can Be Confident That Corentec's (KOSDAQ:104540) Earnings Are High Quality

The subdued stock price reaction suggests that Corentec Co., Ltd.'s ( KOSDAQ:104540 ) strong earnings didn't offer any...
Analysis Article • Dec 23

There's No Escaping Corentec Co., Ltd.'s (KOSDAQ:104540) Muted Revenues Despite A 31% Share Price Rise

Corentec Co., Ltd. ( KOSDAQ:104540 ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Nov 05

Investors Aren't Buying Corentec Co., Ltd.'s (KOSDAQ:104540) Revenues

Corentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...
Analysis Article • Apr 10

Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jan 06

Lacklustre Performance Is Driving Corentec Co., Ltd.'s (KOSDAQ:104540) Low P/S

Corentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...
Analysis Article • Nov 14

Corentec's (KOSDAQ:104540) Returns On Capital Are Heading Higher

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysis Article • Sep 10

Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 28

Corentec Co., Ltd.'s (KOSDAQ:104540) Shares May Have Run Too Fast Too Soon

With a price-to-earnings (or "P/E") ratio of 35.4x Corentec Co., Ltd. ( KOSDAQ:104540 ) may be sending very bearish...
Analysis Article • May 09

These 4 Measures Indicate That Corentec (KOSDAQ:104540) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 31

Returns On Capital Are Showing Encouraging Signs At Corentec (KOSDAQ:104540)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
Analysis Article • Feb 15

Corentec Co., Ltd.'s (KOSDAQ:104540) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Corentec (KOSDAQ:104540) has had a great run on the share market with its stock up by a significant 39% over the last...
Analysis Article • Dec 24

Should You Use Corentec's (KOSDAQ:104540) Statutory Earnings To Analyse It?

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...

Revenue & Expenses Breakdown

How Corentec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A104540 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26102,3772,95636,1383,679
31 Dec 25100,4294,35535,3343,258
30 Sep 2598,0632,61934,3712,960
30 Jun 2592,09035534,2882,506
31 Mar 2589,179-50235,8781,529
31 Dec 2485,594-3,12136,2841,185
30 Sep 2489,419-3,81438,1451,303
30 Jun 2493,262-1,24540,4961,202
31 Mar 2491,9273,24438,3371,528
31 Dec 2392,0464,05538,8811,487
30 Sep 2382,7792,78638,5471,077
30 Jun 2376,0044,36636,706761
31 Mar 2371,1532,12534,443791
31 Dec 2263,9091,78130,288734
30 Sep 2256,3492,64725,919760
30 Jun 2249,64627522,089899
31 Mar 2245,93733521,237-155
31 Dec 2144,63076421,061-196
30 Sep 2144,1591,86919,891-288
30 Jun 2142,8881,61119,406-257
31 Mar 2141,1661,58518,357432
31 Dec 2040,4961,57418,000503
30 Sep 2039,2372,84317,879767
30 Jun 2039,5642,88518,007662
31 Mar 2039,8393,28817,9841,098
31 Dec 1940,1892,50618,2501,152
30 Sep 1935,277-26,72218,044237
30 Jun 1934,180-26,70317,766389
31 Mar 1934,510-28,64719,064447
31 Dec 1833,406-29,76318,483554
30 Sep 1836,247-9,55219,2321,947
30 Jun 1836,589-10,07219,2322,213
31 Mar 1836,568-8,73418,2732,074
31 Dec 1737,634-7,86118,1741,896
30 Sep 1738,24333317,5031,041
30 Jun 1737,683-6617,131590
31 Mar 1737,1577917,088349
31 Dec 1635,97446616,665225
30 Sep 1634,87916915,734311
30 Jun 1634,15034915,548263
31 Mar 1632,017-58214,742173
31 Dec 1530,347-85914,260157
30 Sep 1529,454-92213,81794

Quality Earnings: A104540 has a large one-off loss of ₩3.8B impacting its last 12 months of financial results to 31st March, 2026.

Growing Profit Margin: A104540 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A104540 has become profitable over the past 5 years, growing earnings by -3.2% per year.

Accelerating Growth: A104540 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A104540 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (27.5%).

Return on Equity

High ROE: A104540's Return on Equity (4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/14 08:21
End of Day Share Price 2026/08/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corentec Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa LeeShinhan Investment Corp.